OFFICIAL PUBLICATION OF

by its subsidiary APPco

ACCC vs Pfizer case comes to a close

Sheshtyn Paola 26/10/2018

The High Court has dismissed the ACCC’s application for special leave to appeal in its case against Pfizer Australia over the sale of atorvastatin This month the Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment handed down by the Full Federal Court on 25 May 2018, following a longstanding case

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Wesfarmers targets affordable healthcare

When healthcare is treated as a commodity and patients regarded as consumers, health outcomes are compromised and overall healthcare spending…

Edward Hatfield

ACCC vs Pfizer case comes to a close

Previous A matter of life and death

Next 5 hidden pitfalls in ‘standard’ franchise agreements

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous A matter of life and death

Next 5 hidden pitfalls in ‘standard’ franchise agreements

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.